CWP
TPTX

Concord Wealth Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Concord Wealth Partners’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28
Closed -$2K – 1364
2021
Q3 		$2K Hold
28
– – ﹤0.01% 794
2021
Q2 		$2K Hold
28
– – ﹤0.01% 932
2021
Q1 		$3K Hold
28
– – ﹤0.01% 794
2020
Q4 		$3K Buy
+28
New +$3.07K ﹤0.01% 512

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Concord Wealth Partners's TPTX Position: Q4 2021 in Review

Concord Wealth Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 28 shares — an estimated $2K sold.

Concord Wealth Partners first reported a position in TPTX in Q4 2020 and held it in 4 quarters. The position peaked at $3K in Q1 2021. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

  • Concord Wealth Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Concord Wealth Partners sold 28 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2K.
  • Concord Wealth Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Concord Wealth Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $3K in Q1 2021.
  • 172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Concord Wealth Partners's 13F filing for Q4 2021, filed 21 Jan 2022.